Biotechnology News and Research

RSS

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.

2 Jul 2010

Biomimetic Therapeutics to discuss Augment Bone Graft data results at AOFAS meeting

BioMimetic Therapeutics, Inc. today announced its schedule of events at the American Orthopaedic Foot and Ankle Society (AOFAS) summer meeting being held at the Gaylord National Hotel and Convention Center in National Harbor, Maryland from July 7 - 10, 2010.

2 Jul 2010

Teva launches antidepressant Venlafaxine HCl ER Capsules

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®. The brand product had annual sales of approximately $2.75 billion in the United States, based on IMS sales data.

2 Jul 2010

Roche, X-Chem sign collaborative agreement

X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.

2 Jul 2010

InNexus Biotechnology, NCI amend Collaborative Agreement

InNexus Biotechnology Inc., a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company and the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), have amended the Collaborative Agreement announced on May 27, 2010, involving research on technologies developed by InNexus.

2 Jul 2010

GSK, Genmab amend ofatumumab agreement

GlaxoSmithKline and Genmab A/S announced today an amendment to the ofatumumab co-development and commercialisation agreement. Under the terms of the amendment, GSK will take responsibility for developing ofatumumab in autoimmune indications whilst continuing to jointly develop ofatumumab with Genmab in oncology indications.

2 Jul 2010

USPTO awards Furiex method patent for dapoxetine in treatment of premature ejaculation

Furiex Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office issued a patent on May 18, 2010, for the method for treatment of premature ejaculation using dapoxetine. Furiex developed dapoxetine in collaboration with Alza Corporation and its affiliates. U.S. Patent No. 7,718,705 includes claims directed to dosing dapoxetine on an as-needed basis, capturing the advantage dapoxetine has over other compounds in the same class, which require a pre-loading period for efficacy.

2 Jul 2010

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

United Therapeutics Corporation and Lee's Pharmaceutical Holdings Ltd. announced today that they have entered into an exclusive agreement for the distribution of Remodulin (treprostinil) Injection in China. Remodulin is a subcutaneously or intravenously administered prostacyclin analogue for the treatment of pulmonary arterial hypertension. Lee's Pharmaceutical is a leading Chinese pharmaceutical company with both a strong cardiovascular focus and extensive commercialization experience.

2 Jul 2010

Advanced Analytical opens new sales office, lab in Technologiepark at Heidelberg University

Advanced Analytical, headquartered in Ames, IA, has opened a new sales office and laboratory in Heidelberg Germany. The new facility is located in the Technologiepark on the campus of the Heidelberg University. By opening this office, the company will be able to provide better representation over sales for our suite of products sold as well as provide better support and service for our current and future customer base.

2 Jul 2010

Aptuit to acquire GSK's research business in Verona

GlaxoSmithKline (GSK) and Aptuit, Inc. announced today that they have finalized an agreement for Aptuit to acquire operations at GSK's Medicines Research Centre in Verona, Italy. The arrangement, which is effective as of July 1, 2010, provides for ongoing employment of the staff at the centre and for Aptuit to supply GSK with R&D services from the facilities. Financial terms have not been disclosed.

1 Jul 2010

MPIB researcher makes methodical progress in the area of genetic code engineering

Proteins are the main actors in our body: They transport substances, convey messages or carry out vital processes in their role as molecular machines. The "helmsmen of the cell" are composed of amino acids, whose sequence is already defined by the heritable information in every living being. The translation of this information during the production of proteins (protein synthesis) is determined by the genetic code.

1 Jul 2010

USPTO grants Semafore method patent for PI3K inhibitors

Semafore Pharmaceuticals today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,745,485 entitled "Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways." This patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents.

1 Jul 2010

Follicle aspiration needle Swemed Sense gives less pain, bleeding compared with conventional needle

“The follicle aspiration needle Swemed Sense™ makes it possible to work in a new way, which is more favourable for patients, and at the same time it meets all the other quality requirements for a follicle aspiration needle”

1 Jul 2010

Celsis IVT files patent infringement lawsuit against Invitrogen, CellzDirect

Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against Invitrogen Corporation and CellzDirect, Inc. in the United States District Court for the Northern District of Illinois in Chicago and has moved for a preliminary injunction. Invitrogen, the parent of CellzDirect, is itself a wholly-owned subsidiary of Life Technologies of Carlsbad, California.

1 Jul 2010

CDC issues new guidelines on detection of Mycobacterium tuberculosis infections

Today the United States Centers for Disease Control and Prevention issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, the causative agent of tuberculosis. In these landmark guidelines, CDC advises that Interferon Gamma Release Assay blood tests are now preferred over the 100+-year-old tuberculin skin test for diagnosing TB infection in certain populations, including people who typically do not return for the necessary reading of TST results, and those who have received Bacille Calmette-Guerin as a vaccine or for cancer therapy

1 Jul 2010

Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression

Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.

1 Jul 2010

Pre-clinical data of BiTE antibody technology published in PNAS

Micromet, Inc., today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences, demonstrating the potency of new product candidates based on the Company's proprietary BiTE antibody technology. BiTE antibodies are a new class of agents designed to harness a patient's T cells to kill cancer cells.

1 Jul 2010

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome, and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Biospherics Incorporated, has signed a license agreement with the University of Kentucky Research Foundation (UKRF).

1 Jul 2010

GeoVax Labs postpones proposed public offering

GeoVax Labs, Inc., a biotechnology company dedicated to developing vaccines that prevent and fight human immunodeficiency virus (HIV), today announced that it has decided to postpone its proposed public offering of units, each consisting of a share of common stock and a warrant to purchase another share.

1 Jul 2010

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

1 Jul 2010

Biotechnology News and Research

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Biomimetic Therapeutics to discuss Augment Bone Graft data results at AOFAS meeting

Teva launches antidepressant Venlafaxine HCl ER Capsules

Roche, X-Chem sign collaborative agreement

InNexus Biotechnology, NCI amend Collaborative Agreement

GSK, Genmab amend ofatumumab agreement

USPTO awards Furiex method patent for dapoxetine in treatment of premature ejaculation

United Therapeutics, Lee's Pharmaceutical enter distribution agreement for Remodulin Injection in China

Advanced Analytical opens new sales office, lab in Technologiepark at Heidelberg University

Aptuit to acquire GSK's research business in Verona

MPIB researcher makes methodical progress in the area of genetic code engineering

USPTO grants Semafore method patent for PI3K inhibitors

Follicle aspiration needle Swemed Sense gives less pain, bleeding compared with conventional needle

Celsis IVT files patent infringement lawsuit against Invitrogen, CellzDirect

CDC issues new guidelines on detection of Mycobacterium tuberculosis infections

Evotec commences EVT 101 proof-of-concept Phase II study in treatment-resistant depression

Pre-clinical data of BiTE antibody technology published in PNAS

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

GeoVax Labs postpones proposed public offering

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News